Pacer Advisors’s Janux Therapeutics JANX Stock Holding History

Pacer Advisors’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-439	Closed	-$18.4K	–	2626
2024 Q2	$18.4K	Buy	+439	New	+$20.6K	﹤0.01%	3443

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pacer Advisors's JANX Position: Q3 2024 in Review

Pacer Advisors sold out of Janux Therapeutics (JANX) in Q3 2024, closing a stake of 439 shares — an estimated $18.4K sold.

Pacer Advisors first reported a position in JANX in Q2 2024 and held it in 1 quarter. The position peaked at $18.4K in Q2 2024. 160 funds tracked by Wall St. Rank hold JANX as of Q3 2024.

Pacer Advisors reported no remaining Janux Therapeutics position as of Q3 2024 after selling out during the quarter.
Pacer Advisors sold 439 Janux Therapeutics shares in Q3 2024, an estimated $18.4K.
Pacer Advisors first reported a position in Janux Therapeutics in Q2 2024 and held it in 1 quarter.
Pacer Advisors's Janux Therapeutics position peaked at $18.4K in Q2 2024.
160 funds tracked by Wall St. Rank held Janux Therapeutics as of Q3 2024.

Based on Pacer Advisors's 13F filing for Q3 2024, filed 12 Nov 2024.